Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 28;11(11):CD012905.
doi: 10.1002/14651858.CD012905.pub2.

Fenoldopam for preventing and treating acute kidney injury

Christopher I Esezobor  1   2 , Girish C Bhatt  3 , Emmanuel E Effa  4 , Elisabeth M Hodson  5
Affiliations
Meta-Analysis

Fenoldopam for preventing and treating acute kidney injury

Christopher I Esezobor et al. Cochrane Database Syst Rev. .

Abstract

Background: Fenoldopam is a short-acting benzazepine selective dopaminergic A1 (DA1) receptor agonist with increased activity at the D1 receptor compared with dopamine. Activation of the DA1 receptors increases kidney blood flow because of dilatation of the afferent and efferent arterioles. Previous reviews have been published on the efficacy and safety of fenoldopam for acute kidney injury (AKI); however, they either combined data on its effect on both prevention and treatment of AKI, focused on only those undergoing cardiac surgery and/or excluded children.

Objectives: This review aimed to assess the benefits and harms of fenoldopam for the prevention or treatment of AKI in children and adults.

Search methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 12 November 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria: We included randomised controlled trials (RCTs) evaluating fenoldopam for the prevention or treatment of AKI in children and adults following surgery, radiocontrast exposure or sepsis.

Data collection and analysis: Two authors independently assessed studies for eligibility, assessed the studies for risk of bias and extracted data from the studies. Dichotomous outcomes were presented as relative risk (RR) with 95% confidence intervals (CI). For continuous outcomes, the mean difference (MD) with 95% CI was used. Statistical analysis was performed using the random-effects model. We assessed the certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.

Main results: We identified 25 RCTs, including 3339 randomised participants. Twenty-three studies used fenoldopam for preventing AKI and two for the treatment of AKI. Nine studies included participants undergoing cardiac surgery, and one included children. The risks of bias for sequence generation and concealment were low in 11 and 13 studies, respectively. Only 13 and 18 studies were at low risk of performance bias and detection bias, respectively. The risk of attrition bias and selective reporting were judged to be at low risk of bias in 17 and 10 studies, respectively. We included data in the meta-analyses from eight of the 14 studies comparing fenoldopam with placebo or saline, all six studies comparing fenoldopam with dopamine, all five studies comparing fenoldopam with N-acetylcysteine (NAC) for the prevention of AKI and from the two studies comparing fenoldopam with placebo or saline for the treatment of AKI. Compared with placebo or saline fenoldopam probably results in fewer participants developing AKI (RR 0.72, 95% CI 0.53 to 0.98; 8 studies, 1147 participants; I2 = 48%; moderate certainty) but may make little or no difference to the number requiring kidney replacement therapy (KRT) (RR 0.81, 95% CI 0.31 to 2.15; 7 studies, 835 participants; I2 = 17%), risk of death (RR 0.76, 95% CI: 0.58 to 1.00; 7 studies, 944 participants; I2 = 0%) or change in urine output (SMD 0.20, 95% CI -0.44 to 0.84; 2 studies, 58 participants; I2 = 34%; all low certainty). Fenoldopam may result in a shorter stay in the ICU (MD -1.81 days; 95% CI -2.41 to -1.21; 4 studies, 403 participants; I2 = 0%). It is uncertain whether adverse events (hypotension, myocardial infarction, drug intolerance, cardiac arrhythmias) differed between the treatment groups as the certainty of the evidence was very low. In patients undergoing cardiac surgery, fenoldopam, compared to placebo or saline, may make little or no difference to the prevention of AKI, the need for KRT or death. Compared with dopamine, fenoldopam may make little or no difference to the prevention of AKI (RR 0.62, 95% CI 0.23 to 1.68; 4 studies, 398 participants; I2 = 78%), the number requiring KRT (RR 0.74, 95% CI 0.29 to 1.87; 4 studies, 434 participants; I2 = 0%) or the risk of death (RR 1.27, 95% CI 0.36 to 4.50; 2 studies, 174 participants; I2 = 0%) (all low certainty). It is uncertain whether participants receiving fenoldopam were more likely to develop hypotension compared with those receiving dopamine (RR 3.00, 95% CI 1.06 to 8.52; 1 study, 80 participants; very low certainty). Change in urine output was not reported. It is uncertain whether fenoldopam compared with NAC prevents AKI (RR 1.68, 95% CI 0.79 to 3.56; 3 studies, 359 participants; I2 = 38%), reduces the need for KRT (RR 0.96, 95% CI 0.15 to 6.26; 2 studies, 137 participants; I2 = 0%), or the risk of death (RR 1.05, 95% CI 0.07 to 15.66; 1 study, 39 participants) (all very low certainty). It is uncertain whether hypotension was more frequent with fenoldopam (RR 5.10, 95% CI 0.25, 104.94; 1 study, 192 participants; very low certainty). Change in urine output was not reported. In participants with established AKI, it is uncertain whether fenoldopam compared to placebo or half saline reduces the numbers needing KRT (RR: 0.91, 95% CI 0.54 to 1.54; 2 studies, 822 participants; I2 = 58%; very low certainty) or the risk of death (RR 0.81, 95% CI 0.44 to 1.48; 2 studies, 822 participants; I2 = 66%; very low certainty), or if it increases the risk of hypotension (RR 1.65, 95% CI 1.22 to 2.22; 2 studies, 822 participants; I2 = 0%; very low certainty).

Authors' conclusions: Fenoldopam administration in patients at risk of AKI is probably associated with a lower risk of developing AKI and shorter ICU stay when compared with placebo or saline, but has little or no effect on the need for KRT or the risk of death. In those undergoing cardiac surgery, fenoldopam may not confer any benefits compared with placebo or saline. Furthermore, it remains unclear whether fenoldopam is more or less effective than either dopamine or NAC in reducing the risk for AKI or the need for KRT. Further well-designed and adequately powered studies are required to evaluate the efficacy and safety of fenoldopam in preventing or treating AKI.

Trial registration: ClinicalTrials.gov NCT00122018 NCT01690832 NCT00621790 NCT00743106 NCT00747331 NCT00982527 NCT00467181 NCT00557219 NCT01073189 NCT02620761 NCT00286403.

PubMed Disclaimer

Conflict of interest statement

  1. CIE: no relevant interests were disclosed

  2. GCB: no relevant interests were disclosed

  3. EE: no relevant interests were disclosed

  4. EH: no relevant interests were disclosed

Update of

  • doi: 10.1002/14651858.CD012905

References

References to studies included in this review

Allaqaband 2002 {published data only}
    1. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheterization & Cardiovascular Interventions 2002;57(3):279-83. [MEDLINE: ] - PubMed
Barr 2008 {published data only}
    1. Barr LF, Kolodner K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Critical Care Medicine 2008;36(5):1427-35. [MEDLINE: ] - PubMed
Biancofiore 2004 {published data only}
    1. Biancofiore G, Della Rocca G, Bindi L, Romanelli A, Esposito M, Meacci L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transplantation 2004;10(8):986-92. [MEDLINE: ] - PubMed
Bove 2005 {published data only}
    1. Bove T, Landoni G, Calabro MG, Aletti G, Marino G, Cerchierini E, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005;111(24):3230-5. [MEDLINE: ] - PubMed
Brienza 2006 {published data only}
    1. Brienza N, Malcangi V, Dalfino L, Trerotoli P, Guagliardi C, Bortone D, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Critical Care Medicine 2006;34(3):707-14. [MEDLINE: ] - PubMed
Briguori 2004 {published data only}
    1. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. Journal of the American College of Cardiology 2004;44(4):762-5. [MEDLINE: ] - PubMed
CAFCIN 2006 {published data only}
    1. Ng TM, Shurmur SW, Silver M, Nissen LR, O'Leary EL, Rigmaiden RS, et al. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). International Journal of Cardiology 2006;109(3):322-8. [MEDLINE: ] - PubMed
Caimmi 2003 {published data only}
    1. Caimmi PP, Pagani L, Micalizzi E, Fiume C, Guani S, Bernardi M, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. Journal of Cardiothoracic & Vascular Anesthesia 2003;17(4):491-4. [MEDLINE: ] - PubMed
Cobas 2011 {published data only}
    1. Cobas M, Paparcuri G, De la Pena M, Cudemus G, Barquist E, Varon A. Fenoldopam in critically ill patients with early renal dysfunction. A crossover study. Cardiovascular Therapeutics 2011;29(4):280-4. [MEDLINE: ] - PubMed
    1. Paparcuri G, Cobas M, De la Pena M, Barquist E, Varon A. Fenoldopam in critically ill patients with early renal dysfunction: A crossover study. Dialysis & Transplantation 2011;40(4):164-7. [EMBASE: 361625002] - PubMed
Cogliati 2007 {published data only}
    1. Cogliati AA, Vellutini R, Nardini A, Urovi S, Hamdan M, Landoni G, et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. Journal of Cardiothoracic & Vascular Anesthesia 2007;21(6):847-50. [MEDLINE: ] - PubMed
CONTRAST 2001 {published data only}
    1. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290(17):2284-91. [MEDLINE: ] - PubMed
    1. Stone GW, Tumlin JA, Madyoon H, Lepor NE, McCullough PA, Mathur VS, et al. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Reviews in Cardiovascular Medicine 2001;2 Suppl 1:S31-6. [MEDLINE: ] - PubMed
Della Rocca 2004 {published data only}
    1. Della Rocca G, Pompei L, Costa MG, Coccia C, Scudeller L, Di Marco P, et al. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesthesia & Analgesia 2004;99(6):1604-9. [MEDLINE: ] - PubMed
FANCY 2015 {published data only}
    1. Pristipino C, Pasceri V, Granatelli A, Speciale G, Roncella A, Richichi G, et al. Fenoldopam for prevention of Acute kidNey injury in patients with aCute coronarY syndrome undergoing coronary angiography and/or percutaneous coronary Intervention — The FANCY trial [abstract]. IJC Metabolic & Endocrine 2015;7(Suppl 1):10. [CENTRAL: CN-01658258] [DOI: ]
FENO‐HSR 2010 {published data only}2008‐002077‐12
    1. Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 2014;312(21):2244-53. [MEDLINE: ] - PubMed
    1. Landoni G, Bove T, Pasero D, Comis M, Orando S, Pinelli F, et al. Fenoldopam to prevent renal replacement therapy after cardiac surgery. Design of the FENO-HSR study. HSR Proceedings in Intensive Care & Cardiovascular Anesthesia 2010;2(2):111-7. [MEDLINE: ] - PMC - PubMed
Halpenny 2001 {published data only}
    1. Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten GD. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001;56(10):953-60. [MEDLINE: ] - PubMed
Halpenny 2002 {published data only}
    1. Halpenny M, Rushe C, Breen P, Cunningham AJ, Boucher-Hayes D, Shorten GD. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. European Journal of Anaesthesiology 2002;19(1):32-9. [MEDLINE: ] - PubMed
Memmo 2011 {published data only}
    1. Memmo A, Carozzo A, Landoni G, Fano G, Sottocorna O, Bignami E, et al. Perioperative fenoldopam for the prevention of acute renal failure in non-cardiac surgery, randomized clinical trial. Signa Vitae 2011;6(1):14-9. [EMBASE: 361827595]
Morelli 2005 {published data only}
    1. Morelli A, Ricci Z, Bellomo R, Ronco C, Rocco M, Conti G, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Critical Care Medicine 2005;33(11):2451-6. [MEDLINE: ] - PubMed
O'Hara 2013 {published data only}
    1. Fergany A, O'Hara J, Campbell S, Kaple K, Bonilla A, Mahboobi R. The effect of fenoldopam on renal function in solitary partial nephrectomy surgery [abstract no: 610]. European Urology Supplements 2011;10(2):199. [EMBASE: 70376100]
    1. Fergany A, O'Hara J, Campbell S, Kaple K, Bonilla A. The effect of fenoldopam on renal function in solitary kidney partial nephrectomy [abstract no: 696]. Journal of Urology 2011;185(4 Suppl 1):e280. [EMBASE: 70378099]
    1. O'Hara JF Jr, Mahboobi R, Novak SM, Bonilla AM, Mascha EJ, Fergany AF, et al. Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial. Urology 2013;81(2):340-5. [MEDLINE: ] - PubMed
    1. O'Hara JF, Mascha EJ, Bonilla A. Fenoldopam renal effects in solitary partial nephrectomy [abstract no: 1066503]. Canadian Journal of Anesthesia 2011;58(Suppl 1):S16. [EMBASE: 71888798]
PREVENT 2004 {published data only}
    1. Devine T, Wessman D, Tripp M, Cavendish J, Hall L, Hammes J, et al. A prospective randomized control trial: an evaluation of the use of Fenoldopam (FEN) and N-Acetylcysteine (NAC) with different osmolar contrast agents in the prevention of radiocontrast nephropathy (RCN) (PREVENT STUDY) [abstract no: SA-FC084]. Journal of the American Society of Nephrology 2004;15(Oct):39A. [CENTRAL: CN-00583205]
Ranucci 2010 {published data only}
    1. Ranucci M, Benedetti D, Bianchini C, Castelvecchio S, Ballotta A, Frigiola A, et al. Effects of fenoldopam infusion in complex cardiac surgical operations: A prospective, randomized, double-blind, placebo-controlled study. Minerva Anestesiologica 2010;76(4):249-59. [MEDLINE: ] - PubMed
Ricci 2011 {published data only}
    1. Ricci Z, Luciano R, Favia I, Garisto C, Muraca M, Morelli S, et al. High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Critical Care (London, England) 2011;15(3):R160. [MEDLINE: ] - PMC - PubMed
Tribuzi 2018 {published data only}
    1. Tribuzi S, Bucci LP, Vano V, Naccarato A, Mercieri M. Effects of fenoldopam on renal function in critically ill patients undergoing a strictly conservative strategy of fluid management [abstract no: P170]. Critical Care (London, England) 2018;22(Suppl 1):69. [EMBASE: 621461379]
Tumlin 2002 {published data only}
    1. Tumlin JA, Murray PT, Mathur VS, Wang A. A multicenter, double-blind, placebo-controlled trial of fenoldopam mesylate in the prevention of radiocontrast nephropathy in patients with moderate to severe renal insufficiency [abstract no: A0728]. Journal of the American Society of Nephrology 2000;11(Sept):135A. [CENTRAL: CN-00601911]
    1. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. American Heart Journal 2002;143(5):894-903. [MEDLINE: ] - PubMed
Tumlin 2005 {published data only}
    1. Tumlin J, Finckle K, Murray P, Shaw A. Dopamine receptor 1 agonists in early acute tubular necrosis: a prospective, randomized, double blind, placebo-controlled trial of fenoldopam mesylate [abstract no: PUB001]. Journal of the American Society of Nephrology 2003;14(Nov):774A. [CENTRAL: CN-00583719]
    1. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. American Journal of Kidney Diseases 2005;46(1):26-34. [MEDLINE: ] - PubMed

References to studies excluded from this review

Adluri 2009 {published data only}
    1. Adluri RK, Singh AV, Skoyles J, Robins A, Hitch A, Baker M, et al. The effect of fenoldopam and dopexamine on hepatic blood flow and hepatic function following coronary artery bypass grafting with hypothermic cardiopulmonary bypass. European Journal of Cardio-Thoracic Surgery 2009;35(6):988-94. [MEDLINE: ] - PubMed
    1. Adluri RK, Singh AV, Skoyles J, Robins A, Parton J, Baker M, et al. The effect of fenoldopam and dopexamine on cytokine and endotoxin release following on-pump coronary artery bypass grafting: a prospective randomized double-blind trial. Heart Surgery Forum 2010;13(6):E353-61. [MEDLINE: ] - PubMed
Curtis 1992 {published data only}
    1. Curtis JJ, Laskow DA, Jones P. DA1 receptor agonist lowers renal vascular resistance in kidney transplant patients on cyclosporine [abstract no: 106P]. Journal of the American Society of Nephrology 1992;3(3):855. [CENTRAL: CN-00460601]
NCT00467181 {published data only}
    1. Hochstetler M, Fallon W. A pilot study to investigate fenoldopam usage in the prevention of postoperative renal dysfunction in patients at a high risk for renal impairment during cariopulmonary bypass for cardiac surgery. www.clinicaltrials.gov/ct2/show/NCT00467181 (first received 27 April 2007).
NCT00557219 {published data only}
    1. Klajbor K, Lango R. Fenoldopam and ketanserin for acute kidney failure prevention after cardiac surgery [Influence of fenoldopam and ketanserin on function and kidney injury parameters in patients with increased risk of acute kidney failure after cardiac surgery]. www.clinicaltrials.gov/ct2/show/NCT00557219 (first received 12 November 2007).
NCT01073189 {unpublished data only}
    1. Tumlin J. Intra-renal therapy of diuretic unresponsive acute kidney injury [Effect of combination intra-renal infusion of fenoldopam mesylate and high dose diuretics on peak serum creatinine and incidence of renal replacement therapy in patients with early acute kidney injury]. www.clinicaltrials.gov/ct2/show/NCT01073189 (first received 23 February 2010).
NCT02620761 {unpublished data only}
    1. Segar J. Fenoldopam to prevent renal dysfunction in indomethacin treated preterm infants. www.clinicaltrials.gov/ct2/show/NCT02620761 (first received 3 December 2015).
Sorbello 2007 {published data only}
    1. Sorbello M, Morello G, Paratore A, Cutuli M, Mistretta G, Belluoccio AA, et al. Fenoldopam vs dopamine as a nephroprotective strategy during living donor kidney transplantation: preliminary data. Transplantation Proceedings 2007;39(6):1794-6. [MEDLINE: ] - PubMed
Teirstein 2006 {published data only}
    1. Mathur V, Teirstein P, Anderson E, Croushore L, Madyoon H. Targeted renal drug delivery with fenoldopam: a multicenter, randomized, controlled trial [abstract no: SA-PO211]. Journal of the American Society of Nephrology 2004;15(Oct):346A.
    1. Teirstein PS, Price MJ, Mathur VS, Madyoon H, Sawhney N, Baim DS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. American Journal of Cardiology 2006;97(7):1076-81. [MEDLINE: ] - PubMed
TIFFANY 2005 {published data only}
    1. Teirstein PS, Price MJ, Mathur VS, TIFFANY Study Investigators. Design and rationale for the Targeted Intra-renal Fenoldopam For Avoidance of NephropathY (TIFFANY) trial [abstract no: PUB607]. Journal of the American Society of Nephrology 2005;16:914A. [CENTRAL: CN-00615894]
Tumlin 2008 {published data only}
    1. Tumlin JA, Ellis CD, Himmelfarb JD. Efficacy of combination intrarenal fenoldopam and mesna therapy in contrast nephropathy: a randomized placebo controlled trial [abstract no: SA-PO2981]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):787A.

Additional references

Aravindan 2006
    1. Aravindan N, Samuels J, Riedel B, Shaw A. Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. Kidney & Blood Pressure Research 2006;29(3):165-74. [MEDLINE: ] - PubMed
Bagshaw 2007
    1. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Critical Care & Resuscitation 2007;9(1):60-8. [MEDLINE: ] - PubMed
Bellomo 2004
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care (London, England) 2004;8(4):R204-12. [MEDLINE: ] - PMC - PubMed
Bellomo 2012
    1. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380(9843):756-66. [MEDLINE: ] - PubMed
Bhat 2006
    1. Bhat MA, Shah ZA, Makhdoomi MS, Mufti MH. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. Journal of Pediatrics 2006;149(2):180-4. [MEDLINE: ] - PubMed
Brogden 1997
    1. Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs 1997;54(4):634-50. [DOI: 10.2165/00003495-199754040-00008] [PMID: ] - DOI - PubMed
Coca 2012
    1. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney International 2012;81(5):442-48. [MEDLINE: ] - PMC - PubMed
De Backer 2002
    1. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. American Journal Respiratory & Critical Care Medicine 2002;166(1):98-104. [MEDLINE: ] - PubMed
Gillies 2015
    1. Gillies MA, Kakar V, Parker RJ, Honore PM, Ostermann M. Fenoldopam to prevent acute kidney injury after major surgery- a systematic review and meta-analysis. Critical Care (London, England) 2015;19:449. [MEDLINE: ] - PMC - PubMed
Girbes 1990
    1. Girbes AR, Smit AJ, Meijer S, Reitsma WD. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 1990;56(2):179-15. [MEDLINE: ] - PubMed
Goldberg 1984
    1. Goldberg LI. Dopamine receptors and hypertension. Physiologic and pharmacologic implications. American Journal of Medicine 1984;77(4A):37-44. [MEDLINE: ] - PubMed
GRADE 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: ] - PMC - PubMed
GRADE 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: ] - PubMed
Greenberg 2009
    1. Greenberg A. Primer on Kidney Diseases. 5th edition. Philadelphia: Saunders, 2009. [EBOOK ISBN: 9781437721102]
Hahn 1982
    1. Hahn RA, Wardell JR Jr, Sarau HM, Ridley PT. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. Journal of Pharmacology & Experimental Therapeutics 1982;223(2):305-13. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: ] - PMC - PubMed
Higgins 2022
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
KDIGO 2012
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney International - Supplement 2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1] - DOI
Kerr 2014
    1. Kerr M, Bedford M, Matthews B, O'Donoghue D. The economic impact of acute kidney injury in England. Nephrology Dialysis Transplantation 2014;29(7):1362-8. [MEDLINE: ] - PubMed
Kondabolu 2023
    1. Kondabolu S, Kakarlapudi Y, Malik H, Malik H, Khan S, Komminni P, et al. Beneficial impacts of fenoldopam on patients with or at risk for acute renal failure and undergoing surgery: a meta-analysis of randomized clinical trials. Cureus 2023;15(2):e34584. [DOI: 10.7759/cureus.34584] [PMID: ] - DOI - PMC - PubMed
Landoni 2007
    1. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabrò MG, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. American Journal of Kidney Diseases 2007;49(1):56-68. [MEDLINE: ] - PubMed
Landoni 2008
    1. Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. Journal of Cardiothoracic & Vascular Anesthesia 2008;22(1):27-33. [MEDLINE: ] - PubMed
Lassnigg 2004
    1. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. Journal of the American Society of Nephrology 2004;15(6):1597-605. [MEDLINE: ] - PubMed
Levy 2005
    1. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, et al. Early changes in organ function predict eventual survival in severe sepsis. Critical Care Medicine 2005;33(10):2194-201. [MEDLINE: ] - PubMed
Mehta 2007
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care (London, England) 2007;11(2):R31. [MEDLINE: ] - PMC - PubMed
Mehta 2016
    1. Mehta RL, Burdmann EA, Cerda J, Feehally J, Finkelstein F, Garcia-Garcia G, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study [Erratum in: Lancet. 2016 May 14;387(10032):1998]. Lancet 2016;387(10032):2017-25. [MEDLINE: ] - PubMed
Molnar 2011
    1. Molnar AO, Coca SG, Devereaux PJ, Jain AK, Kitchlu A, Luo J, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. Journal of the American Society of Nephrology 2011;22(5):939-46. [MEDLINE: ] - PMC - PubMed
Nigwekar 2009
    1. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD006028. [DOI: 10.1002/14651858.CD006028.pub2] - DOI - PubMed
Olowu 2016
    1. Olowu WA, Niang A, Osafo C, Ashuntantang G, Arogundade FA, Porter J, et al. Outcomes of acute kidney injury in children and adults in sub-Saharan Africa: a systematic review. The Lancet Global Health 2016;4(4):e242-50. [MEDLINE: ] - PubMed
Pollock 1990
    1. Pollock DM, Arendshorst WJ. Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation. American Journal of Physiology 1990;258(3 Pt 2):F627-35. [MEDLINE: ] - PubMed
Schünemann 2022a
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Schünemann 2022b
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Singer 1998
    1. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. American Journal of Kidney Diseases 1998;31(5):743-55. [MEDLINE: ] - PubMed
Su 2017
    1. Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, et al. Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and bayesian network meta-analysis. American Journal of Kidney Diseases 2017;69(1):69-77. [PMID: ] - PubMed
Sun 2019
    1. Sun H, Xie Q, Peng Z. Does fenoldopam protect kidney in cardiac surgery? A systemic review and meta-analysis with trial sequential analysis. Shock 2019;52(3):326-33. [PMID: ] - PubMed
Susantitaphong 2013
    1. Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al. World incidence of AKI: a meta-analysis.[Erratum appears in Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1148]. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(9):1482-93. [MEDLINE: ] - PMC - PubMed
Tiwari 2005
    1. Tiwari MM, Brock RW, Megyesi JK, Kaushal GP, Mayeux PR. Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure: role of nitric oxide and caspases. American Journal of Physiology - Renal Physiology 2005;289(6):F1324-32. [MEDLINE: ] - PubMed
Uchino 2005
    1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294(7):813-8. [MEDLINE: ] - PubMed
Wang 2012
    1. Wang Z, Holthoff JH, Seely KA, Pathak E, Spencer HJ 3rd, Gokden N, et al. Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injury. American Journal of Pathology 2012;180(2):505-16. [MEDLINE: ] - PMC - PubMed
Weber 1988
    1. Weber RR, McCoy CE, Ziemniak JA, Frederickson ED, Goldberg LI, Murphy MB. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. British Journal of Clinical Pharmacology 1988;25(1):17-21. [MEDLINE: ] - PMC - PubMed
Yang 2014
    1. Yang B, Xu J, Xu F, Zou Z, Ye C, Mei C, et al. Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis. PLoS ONE (Electronic Resource] 2014;9(1):e85029. [MEDLINE: ] - PMC - PubMed
Zacharias 2013
    1. Zacharias M, Mugawar M, Herbison GP, Walker RJ, Hovhannisyan K, Sivalingam P, et al. Interventions for protecting renal function in the perioperative period. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No: CD003590. [DOI: 10.1002/14651858.CD003590.pub4] - DOI - PMC - PubMed
Zangrillo 2012
    1. Zangrillo A, Biondi-Zoccai GG, Frati E, Covello RD, Cabrini L, Guarracino F, et al. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. Journal of Cardiothoracic & Vascular Anesthesia 2012;26(3):407-13. [MEDLINE: ] - PubMed
Ziemniak 1987
    1. Ziemniak JA, Allison N, BoPpana VK, Dubb J, Stote R. The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation. Clinical Pharmacology & Therapeutics 1987;41(3):275-81. [PMID: ] - PubMed

References to other published versions of this review

Esezobor 2017
    1. Esezobor CI, Bhatt GC, Effa EE, Hodson EM. Fenoldopam for preventing and treating acute kidney injury. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No: CD012905. [DOI: 10.1002/14651858.CD012905] - DOI - PMC - PubMed

MeSH terms

Associated data

LinkOut - more resources